Results 311 to 320 of about 355,709 (346)

Cemiplimab (Libtayo) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has approved cemiplimab-rwlc (Libtayo – Regeneron), an immune checkpoint inhibitor, for use in combination with platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 aberrations
openaire   +2 more sources

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.

New England Journal of Medicine
BACKGROUND Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)-mutated advanced non ...
B. Cho, Shun Lu, E. Felip, Alexander I Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Y. Ostapenko, P. Danchaivijitr, Baogang Liu, A. Alip, E. Korbenfeld, J. Mourão Dias, B. Besse, K. Lee, Hailin Xiong, S. How, Ying Cheng, G-C. Chang, Hiroshige Yoshioka, J. Yang, Michael Thomas, D. Nguyen, Sai-Hong Ignatius Ou, Sanjay Mukhedkar, K. Prabhash, M. D'Arcangelo, Jorge Alatorre-Alexander, J. C. Vázquez Limón, Sara Alves, D. Stroyakovskiy, Marina Peregudova, M. Şendur, O. Yazıcı, R. Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, A. Passaro, Sang-We Kim, S. Gadgeel, John Xie, T. Sun, Melissa Martinez, M. Ennis, Elizabeth Fennema, M. Daksh, D. Millington, Isabelle Leconte, Ryota Iwasawa, Patricia A. Lorenzini, Mahadi Baig, Sujay Shah, Joshua M. Bauml, S. M. Shreeve, S. Sethi, R. Knoblauch, H. Hayashi   +56 more
semanticscholar   +1 more source

Capmatinib (Tabrecta) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases.
openaire   +2 more sources

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

New England Journal of Medicine
BACKGROUND Osimertinib is a recommended treatment for advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated NSCLC.
Shun Lu, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, N. Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, J. Yang, M. Cobo, M. Özgüroğlu, I. Casarini, Dang-Van Khiem, V. Sriuranpong, E. Cronemberger, Toshiaki Takahashi, Yotsawaj Runglodvatana, Ming Chen, Xiangning Huang, Ellie Grainger, D. Ghiorghiu, T. van der Gronde, Suresh S. Ramalingam   +23 more
semanticscholar   +1 more source

Sotorasib (Lumakras) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
Sotorasib (Lumakras — Amgen), an oral KRAS inhibitor, has received accelerated approval by the FDA for treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who received at least one prior systemic therapy.
openaire   +2 more sources

Assessing Toripalimab in NSCLC

Cancer Discovery, 2022
Abstract According to CHOICE-01, a phase III trial in China, the PD-1 inhibitor toripalimab plus chemotherapy improves progression-free survival in patients with untreated non–small cell lung cancer lacking actionable mutations. The findings boost combination chemo–immunotherapy, rather than chemotherapy alone, as the new standard for ...
openaire   +2 more sources

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

Cancer Discovery, 2020
EGFR exon 20 insertion driver mutations (Exon20ins) in NSCLC are insensitive to EGFR-TKIs. Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR/cMet, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing ...
J. Yun, Soo-Hwan Lee, Seok-Young Kim, Seonhyang Jeong, Jae-Hwan Kim, K. Pyo, Chaewon Park, S. Heo, M. Yun, Sangbin Lim, S. Lim, M. Hong, H. R. Kim, M. Thayu, J. Curtin, R. Knoblauch, M. V. Lorenzi, A. Roshak, B. Cho   +18 more
semanticscholar   +1 more source

Multimodality Therapy for NSCLC

2016
The standard therapy for patients with unrespectable stage III non-small-cell lung cancer (NSCLC) is the combination of chemotherapy and radiotherapy. Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains ...
Saiama N. Waqar, Lingling Du, Daniel Morgensztern   +2 more
openaire   +3 more sources

Perspectives in adjuvant chemotherapy in NSCLC

Expert Review of Respiratory Medicine, 2007
In 2007 the long-term outcome of lung cancer is still disappointing, with a 5-year survival rate not exceeding 15%. However, small but significant improvements in survival times have been achieved in the last decade. This progress has been achieved through the improvement of surgical techniques and following the introduction of more effective ...
Selvaggi, Giovanni, Scagliotti, Giorgio Vittorio   +1 more
openaire   +4 more sources

Adjuvant and neoadjuvant treatments for NSCLC

Lung Cancer, 2002
In stage III non-small cell lung cancer (NSCLC), the use of induction chemotherapy prior to radiotherapy produces a significant increase in median survival of three to four months (from 11 to 14 months), a benefit which appears to be achieved through improved systemic control of the disease.
David R. Gandara, Hak Choy, Karin Mattson, Everett E. Vokes   +3 more
openaire   +3 more sources